OMIC vs. QSI, NAUT, KEQU, FEIM, SEER, RPID, INTT, ODYS, AKYA, and OWLT
Should you be buying Singular Genomics Systems stock or one of its competitors? The main competitors of Singular Genomics Systems include Quantum-Si (QSI), Nautilus Biotechnology (NAUT), Kewaunee Scientific (KEQU), Frequency Electronics (FEIM), Seer (SEER), Rapid Micro Biosystems (RPID), inTEST (INTT), Odysight.Ai (ODYS), Akoya Biosciences (AKYA), and Owlet (OWLT). These companies are all part of the "measuring and control equipment" industry.
Singular Genomics Systems vs.
Singular Genomics Systems (NASDAQ:OMIC) and Quantum-Si (NASDAQ:QSI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment.
Singular Genomics Systems has a net margin of -3,237.89% compared to Quantum-Si's net margin of -3,968.84%. Quantum-Si's return on equity of -36.96% beat Singular Genomics Systems' return on equity.
Singular Genomics Systems has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Quantum-Si has a beta of 2.69, suggesting that its stock price is 169% more volatile than the S&P 500.
Singular Genomics Systems has higher revenue and earnings than Quantum-Si. Quantum-Si is trading at a lower price-to-earnings ratio than Singular Genomics Systems, indicating that it is currently the more affordable of the two stocks.
Singular Genomics Systems currently has a consensus target price of $10.75, indicating a potential downside of 46.28%. Quantum-Si has a consensus target price of $3.42, indicating a potential upside of 162.82%. Given Quantum-Si's stronger consensus rating and higher possible upside, analysts plainly believe Quantum-Si is more favorable than Singular Genomics Systems.
65.8% of Singular Genomics Systems shares are owned by institutional investors. Comparatively, 39.9% of Quantum-Si shares are owned by institutional investors. 22.2% of Singular Genomics Systems shares are owned by insiders. Comparatively, 30.0% of Quantum-Si shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Singular Genomics Systems received 5 more outperform votes than Quantum-Si when rated by MarketBeat users. However, 72.73% of users gave Quantum-Si an outperform vote while only 44.83% of users gave Singular Genomics Systems an outperform vote.
In the previous week, Quantum-Si had 10 more articles in the media than Singular Genomics Systems. MarketBeat recorded 11 mentions for Quantum-Si and 1 mentions for Singular Genomics Systems. Singular Genomics Systems' average media sentiment score of 0.63 beat Quantum-Si's score of 0.33 indicating that Singular Genomics Systems is being referred to more favorably in the media.
Summary
Quantum-Si beats Singular Genomics Systems on 11 of the 18 factors compared between the two stocks.
Get Singular Genomics Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMIC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Singular Genomics Systems Competitors List
Related Companies and Tools
This page (NASDAQ:OMIC) was last updated on 3/4/2025 by MarketBeat.com Staff
Free OMIC Stock Alerts